title: Reversible cardiomyopathy following treatment with amphotericin B and flucytosine.
authors.forename: Rena E
authors.initials: RE
authors.lastname: Johnson
authors.forename: Stacy
authors.initials: S
authors.lastname: Campbell-Bright
authors.forename: Ralph H
authors.initials: RH
authors.lastname: Raasch
authors.forename: Jo E
authors.initials: JE
authors.lastname: Rodgers
authors.forename: Beth S
authors.initials: BS
authors.lastname: Rosenberg
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy; D004337:Drug Carriers; D004562:Electrocardiography; D005260:Female; D005437:Flucytosine / Q000009:adverse effects* / Q000627:therapeutic use; D006321:Heart / Q000000981:diagnostic imaging; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D011877:Radionuclide Imaging
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B; D005437:Flucytosine